Related Experiment Video
Updated: Aug 24, 2026

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
Published on: February 2, 2021
What can be done about acute renal failure?
1Department of Critical Care Medicine, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania 15261, USA. kellumja@ccm.upmc.edu
Abstract:
Acute renal failure (ARF) complicates the clinical course of as many as 5% of all hospitalized patients with the critically ill and injured disproportionably at risk. Considerable effort has been expended to develop techniques to prevent ARF or to facilitate its resolution. However, to date, studies have failed to demonstrate that drugs can prevent onset or deterioration of renal function in the critically ill, and some studies have even suggested harm. Recent data suggest that NAC can reduce the incidence of ARF secondary to radio-contrast agents and improved techniques for RRT and, perhaps, new drugs aimed at improving cellular repair, will improve outcome from ARF in the future.
Insights
Acute renal failure (ARF) affects 5% of hospitalized patients. While drugs have not prevented ARF, N-acetylcysteine (NAC) may reduce contrast-induced ARF, with future treatments focusing on cellular repair.
Area of Science:
- Nephrology
- Critical Care Medicine
Background:
- Acute renal failure (ARF) is a common complication in critically ill patients, affecting up to 5% of those hospitalized.
- Despite extensive research, pharmacological interventions to prevent ARF or preserve renal function in the critically ill have largely failed, with some even showing detrimental effects.
Purpose of the Study:
- To review the current understanding of ARF in critically ill patients.
- To evaluate the efficacy of existing and potential future treatments for ARF.
Main Methods:
- Review of existing literature on ARF in critically ill patients.
- Analysis of studies investigating pharmacological interventions and supportive care for ARF.
Main Results:
- Current drug therapies have not proven effective in preventing ARF onset or progression in critically ill individuals.
- Emerging evidence suggests N-acetylcysteine (NAC) may decrease ARF incidence related to radiocontrast agents.
- Advancements in renal replacement therapy (RRT) and novel drugs targeting cellular repair hold promise for improving ARF outcomes.
Conclusions:
- Pharmacological prevention of ARF in the critically ill remains a significant challenge.
- N-acetylcysteine (NAC) shows potential in specific ARF contexts, such as contrast-induced nephropathy.
- Future improvements in ARF management likely depend on enhanced RRT techniques and therapies promoting renal cellular repair.
Related Concept Videos
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute Kidney Injury I: Introduction
Acute Kidney Injury VI: Nursing Management
Acute Kidney Injury II: Pathophysiology